None of the current methods effectively serve the need of massive epidemiological surveillance. To make a difference in this area, Syngene has tied-up with the Centre for Cellular and Molecular Biology for jointly developing and validating a high throughput assay using deep sequencing. This model will be able to take 5,000 to 25,000 samples in one run on next generation sequencing (NGS) platforms such as NextSeq and NovaSeq. This method is also expected to be at least 25% less expensive than existing RT-PCR methods.